Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study

Pae, Chi‐Un; Serretti, Alessandro; Chiesa, Alberto; Mandelli, Laura; Lee, Changuk; Lee, Chul; Kim, Jung-Jin; Ronchi, Diana De; Paik, In‐Ho

doi:10.1016/j.euroneuro.2009.04.002

Cited by 50 publications

(47 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the following analysis, we thus systematically controlled for them to reduce possible sources of variance. As previously observed, 15 severity scores significantly improved during the study whereas no significant difference was observed for side effects.…”

Section: Discussionsupporting

confidence: 83%

“…15 Briefly, out of 177 screened schizophrenia inpatients or outpatients according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria, 87 were included into the intent-to-treat sample. Patients were eligible for inclusion if their symptoms were not optimally controlled and/or if they did not tolerate current antipsychotic medications well.…”

Section: Sample Descriptionmentioning

confidence: 99%

“…No significant difference in the number of benzodiazepines' users and dosage administered was found among the three groups. 15 The study protocol, including genetic analysis, was approved by the institutional review board of Kangnam St Mary's Hospital.…”

Section: Sample Descriptionmentioning

confidence: 99%

See 2 more Smart Citations

No influence of FAT polymorphisms in response to aripiprazole

et al. 2009

Self Cite

View full text Add to dashboard Cite

The aim of this study was to investigate possible influences of a set of markers in the FAT gene (rs2306987, rs2306990, rs2637777 and rs2304865) on efficacy and tolerability of aripiprazole in the treatment of schizophrenic patients. Efficacy was assessed at baseline and weeks 1, 2, 4, 6, 8 and 12 using the Clinical Global Impression Severity and Improvement scale (CGI-S; CGI-I), the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms scale. Side effects were evaluated by means of the Simpson-Angus Scale for Extrapyramidal Symptoms, the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale. Multivariate analyses were employed to test possible influences of single nucleotide polymorphisms on clinical and safety variables. Analysis of haplotypes was also performed. No relevant association between FAT variants and clinical or safety scores was observed. Haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well. Our data suggest no association between investigated alleles and genotypes in FAT and response to aripiprazole. However, because several limitations characterize the present study, further investigations on larger studies are required.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Sample Descriptionmentioning

confidence: 99%

See 1 more Smart Citation

No influence of FAT polymorphisms in response to aripiprazole

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…More than half of the patients included in the current study experienced exacerbation of psychotic symptoms after being switched to the aripiprazole medication regime, a phenomenon that has been described in other reports [Adan-Manes and GarciaParajua, 2009;Pae et al 2009;Ramaswamy et al 2004]. As suggested by Adan-Manes and GarciaParajua, chronic administration of dopamine antagonists in these patients may have induced hypersensitivity to the agonistic effects of aripiprazole, resulting in a worsening of psychotic symptoms in response to aripiprazole treatment.…”

Section: Discussionmentioning

confidence: 62%

Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports

Lataster

Myin-Germeys

Wichers

et al. 2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Background: Blockade of the dopamine D 2 receptor is a key mechanism in the antipsychotic treatment of patients with a psychotic disorder, but may also induce emotional deficits. The partial D 2 agonistic profile of aripiprazole has, therefore, been suggested to favor emotional wellbeing compared with the pure dopamine antagonistic properties of traditional antipsychotics. Method: The current study used the experience sampling method (a structured diary technique) to assess the effects of switching from treatment with traditional dopamine antagonist antipsychotics to treatment with the partial dopamine agonist aripiprazole on emotional wellbeing in the daily life of 13 patients with a diagnosis of schizophrenia. Results: More than half of all patients experienced exacerbation of psychotic symptoms after they had switched to the aripiprazole medication regime, consequently resulting in dropout of the study. Furthermore, switching to aripiprazole treatment, when effective in terms of symptom reduction, was accompanied by decreased feelings of both positive and negative affect in daily life, suggestive of a general state of emotional dampening. Conclusions: Although the scale of the current study and the 54% dropout rate call for careful interpretation of the data, implementation of ecological monitoring in psychopharmacological research may open up new avenues for untangling the working mechanisms of compounds with regard to their impact on mental states.

show abstract

“…A detailed sample description has been reported in a previous paper [11] . Briefly, out of 177 screened schizophrenic inpatients or outpatients according to DSM-IV criteria, 87 were included into the intent-to-treat sample.…”

Section: Sample Descriptionmentioning

confidence: 99%

No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole

et al. 2010

Self Cite

View full text Add to dashboard Cite

Aims: The aim of the present study was to investigate pos- sible influences of a panel of markers in the dysbindin gene DTNBP1 (rs3213207, rs1011313, rs2005976, rs760761 and rs2619522) on the clinical outcome and side effects associated to the treatment with aripiprazole in schizophrenic patients. Methods: Efficacy was assessed at baseline and weeks 1, 2, 4, 6 and 8 using the Clinical Global Impression Severity and Improvement Scales, the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms. Side effects were evaluated by the Simpson-Angus, Barnes Akathisia and Abnormal Involuntary Movement Scales. Multivariate analysis of covariance was used to test possible influences of single nucleotide polymorphisms on clinical and safety scores. Analysis of haplotypes was also performed. Results: No relevant association between DTNBP1 variants and clinical or safety scores was observed. Additionally, haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well. Conclusion: Our data suggest no association between the investigated alleles and genotypes in DTNBP1 and the response to aripiprazole. However, because several limitations characterize the present study, further investigations are required.

show abstract

Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study

Cited by 50 publications

References 21 publications

No influence of FAT polymorphisms in response to aripiprazole

No influence of FAT polymorphisms in response to aripiprazole

Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports

No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole

Contact Info

Product

Resources

About